FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955149162> ?p ?o ?g. }

• W2955149162 endingPage "S390" @default.
• W2955149162 startingPage "S390" @default.
• W2955149162 abstract "The treatment landscape for mHNSCC expanded with the approval of IO therapies. This study describes real-world treatment patterns in mHNSCC. Adults (age ≥18) who initiated IO (nivolumab or pembrolizumab) between 2/1/2016-11/30/2017 were identified in the IQVIA Real-World Data Adjudicated Claims–USTM database; first date of IO was the index date. Patients had ≥2 HNSCC diagnoses (≥30 days apart), ≥12 (up to 24) months of pre-index, ≥30 days of post-index, and ≥1 pre-index metastatic cancer diagnosis. Treatment patterns before and after IO initiation were described. 416 patients were identified (mean age 59 years, 78% male, 80% had ≥2 metastases in pre-index period). About 51%, 25%, and 9% of patients had 1, 2, or ≥3 treatment regimens prior to IO, respectively (median pre-index duration: 24 months). The most commonly observed initial, second, and third regimens before IO initiation were chemotherapy from one therapeutic class (e.g., platinum-based/taxane) (43%, 26%, 40%, respectively) or two therapeutic classes in combination (25%, 28%, 29%, respectively). Median durations of the pre-index regimens ranged from 2.5-3.3 months. 404 (97%) patients initiated IO as monotherapy and 12 (3%) initiated IO combined with other systemic treatments. The median duration of the index IO regimen was 3 months. 118 (28%) patients had subsequent regimens. The most common were single-class chemotherapy (n=33, 28%) and IO monotherapy (n=27, 23%), among which 22 patients restarted the index IO, 3 switched from pembrolizumab to nivolumab, and 2 switched from nivolumab to pembrolizumab. In real-world practice, most mHNSCC patients received ≥1 treatment regimen before IO, frequently chemotherapy from one therapeutic class, and the most common IO regimen initiated was monotherapy. Approximately one-fourth of patients with a subsequent regimen restarted their index IO or switched to another IO monotherapy. Future studies on IO treatment patterns and outcomes with longer follow-up are recommended." @default.
• W2955149162 created "2019-07-12" @default.
• W2955149162 creator A5025682014 @default.
• W2955149162 creator A5034673183 @default.
• W2955149162 creator A5043779414 @default.
• W2955149162 creator A5059381074 @default.
• W2955149162 creator A5086351627 @default.
• W2955149162 date "2019-05-01" @default.
• W2955149162 modified "2023-09-26" @default.
• W2955149162 title "TP4 REAL-WORLD TREATMENT PATTERNS FOR PATIENTS WITH METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (MHNSCC) TREATED WITH IMMUNO-ONCOLOGY (IO) THERAPY" @default.
• W2955149162 doi "https://doi.org/10.1016/j.jval.2019.04.1908" @default.
• W2955149162 hasPublicationYear "2019" @default.
• W2955149162 type Work @default.
• W2955149162 sameAs 2955149162 @default.
• W2955149162 citedByCount "0" @default.
• W2955149162 crossrefType "journal-article" @default.
• W2955149162 hasAuthorship W2955149162A5025682014 @default.
• W2955149162 hasAuthorship W2955149162A5034673183 @default.
• W2955149162 hasAuthorship W2955149162A5043779414 @default.
• W2955149162 hasAuthorship W2955149162A5059381074 @default.
• W2955149162 hasAuthorship W2955149162A5086351627 @default.
• W2955149162 hasBestOaLocation W29551491621 @default.
• W2955149162 hasConcept C121608353 @default.
• W2955149162 hasConcept C126322002 @default.
• W2955149162 hasConcept C143998085 @default.
• W2955149162 hasConcept C2777511904 @default.
• W2955149162 hasConcept C2777701055 @default.
• W2955149162 hasConcept C2780030458 @default.
• W2955149162 hasConcept C2780057760 @default.
• W2955149162 hasConcept C2781413609 @default.
• W2955149162 hasConcept C530470458 @default.
• W2955149162 hasConcept C71924100 @default.
• W2955149162 hasConceptScore W2955149162C121608353 @default.
• W2955149162 hasConceptScore W2955149162C126322002 @default.
• W2955149162 hasConceptScore W2955149162C143998085 @default.
• W2955149162 hasConceptScore W2955149162C2777511904 @default.
• W2955149162 hasConceptScore W2955149162C2777701055 @default.
• W2955149162 hasConceptScore W2955149162C2780030458 @default.
• W2955149162 hasConceptScore W2955149162C2780057760 @default.
• W2955149162 hasConceptScore W2955149162C2781413609 @default.
• W2955149162 hasConceptScore W2955149162C530470458 @default.
• W2955149162 hasConceptScore W2955149162C71924100 @default.
• W2955149162 hasLocation W29551491621 @default.
• W2955149162 hasOpenAccess W2955149162 @default.
• W2955149162 hasPrimaryLocation W29551491621 @default.
• W2955149162 hasRelatedWork W2155654588 @default.
• W2955149162 hasRelatedWork W2296139876 @default.
• W2955149162 hasRelatedWork W2811288290 @default.
• W2955149162 hasRelatedWork W2954103552 @default.
• W2955149162 hasRelatedWork W3048765634 @default.
• W2955149162 hasRelatedWork W3185931698 @default.
• W2955149162 hasRelatedWork W3206642851 @default.
• W2955149162 hasRelatedWork W4212796756 @default.
• W2955149162 hasRelatedWork W4224862170 @default.
• W2955149162 hasRelatedWork W4312129293 @default.
• W2955149162 hasVolume "22" @default.
• W2955149162 isParatext "false" @default.
• W2955149162 isRetracted "false" @default.
• W2955149162 magId "2955149162" @default.
• W2955149162 workType "article" @default.